Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur
40,12
EUR
+0,11 % +0,05
13:49:41 Uhr,
L&S Exchange
Kommentare 50.311
Terminal4321,
Montag 15:20 Uhr
0
Die Bude soll auf Teufel komm raus nicht mehr steigen. Fragt sich nur warum 🤔
McLovin09,
Montag 14:18 Uhr
1
Novo agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI startup to potentially speed its development
McLovin09,
Montag 11:28 Uhr
5
Ich glaube das schlimmste haben wir jetzt hinter uns. Meine Taschen sind voll, jetzt heißt es zurücklehnen und genießen/ abwarten
McLovin09,
Montag 11:27 Uhr
0
Earlier I tweeted that SB1 Markets raised its price target on $NVO to DKK 350. Here is some more color on why.
SB1 says the market still underestimates Novo’s growth potential, especially after the strong oral Wegovy launch.
According to the bank, ~80% of oral Wegovy users are new to obesity treatment, which they see as a clear sign the market is expanding rather than just shifting from injections.
SB1 expects Novo’s sales growth to improve from -8% in 2026 to +6% in 2027 and +13% in 2028, well above consensus expectations.
#stocks #investing
McLovin09,
Montag 10:56 Uhr
0
Novo Nordisk needs Inventage Lab's tech ASAP!
A Korean company called Inventage Lab just registered a patent for oral Semaglutide. Current oral meds like Rybelsus and Foundayo have a terrible 1% bioavailability. But this new tech showed 14x higher exposure than the control!
McLovin09,
Montag 10:52 Uhr
2
$NVO $NOVO Nordea attended Novo Nordisk's Meet-the-Management on Thursday in London and noted several interesting points during the day.
Firstly, Novo Nordisk is sharpening its commercial focus on building a brand around Wegovy rather than being a GLP-1 producer. An important difference in Nordea's opinion.
In this context, it is interesting that Wegovy is becoming the leading household brand in obesity treatment in the US according to Google Trends, with the shift in trend visible around the turn of the year.
This is in line with the development in prescriptions, where Novo Nordisk continues to show solid demand for Wegovy (pill), while Eli Lilly's launch of Foundayo remains subdued, Nordea notes.
Nordea also understands from the sessions that the volume increase from the Medicare Part D bridge program in H2 2026 is only an insignificant part of Novo Nordisk's own expectations - at least at the low end of the range.
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Novo Nordisk nach Split | ||
| 2 | Novo Nordisk |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | ALMONTY INDUSTRIES INC. Hauptdiskussion | -0,56 % | |
| 2 | SAP Hauptdiskussion | +0,54 % | |
| 3 | DAX Hauptdiskussion | +1,00 % | |
| 4 | YNVISIBLE INTERACTIVE Hauptdiskussion | +4,83 % | |
| 5 | Poet Technologies | +25,54 % | |
| 6 | Atyr Pharma | +12,35 % | |
| 7 | Ecograf - ein Stern am Graphithimmel | -2,99 % | |
| 8 | RHEINMETALL Hauptdiskussion | +1,78 % | |
| 9 | MICRON TECHNOLOGY Hauptdiskussion | -0,21 % | |
| 10 | Gamestop ein Leerlauf? | +0,24 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | ALMONTY INDUSTRIES INC. Hauptdiskussion | -0,56 % | |
| 2 | SAP Hauptdiskussion | +0,54 % | |
| 3 | YNVISIBLE INTERACTIVE Hauptdiskussion | +4,83 % | |
| 4 | Poet Technologies | +28,22 % | |
| 5 | Atyr Pharma | +13,24 % | |
| 6 | Ecograf - ein Stern am Graphithimmel | -2,99 % | |
| 7 | Gamestop ein Leerlauf? | +0,29 % | |
| 8 | MICRON TECHNOLOGY Hauptdiskussion | +0,58 % | |
| 9 | RHEINMETALL Hauptdiskussion | +1,75 % | |
| 10 | Klarna - Hauptforum | +4,39 % | Alle Diskussionen |